Potential First U.S. Gene Therapy Now Under FDA Review

Share this content:
Potential First U.S. Gene Therapy Now Under FDA Review
Potential First U.S. Gene Therapy Now Under FDA Review

THURSDAY, July 13, 2017 (HealthDay News) -- The potential first gene therapy in the United States is being reviewed by a U.S. Food and Drug Administration expert panel.

At the Wednesday meeting, the panel will assess the safety, effectiveness, and production of the one-time treatment for children and young adults with advanced leukemia, the Associated Press reported.

The experimental gene therapy drug was developed by the University of Pennsylvania and Novartis and is called tisagenlecleucel (CTL019). It involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19-expressing malignant and non-malignant cells.

After reviewing the data, the panel will vote on whether to recommend FDA approval, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Florida Teen First Human Case of Another Mosquito-Borne Virus

Florida Teen First Human Case of Another Mosquito-Borne ...

First documented case of Keystone infection in a human

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

70 Sickened So Far in Salmonella-Tainted Melon Outbreak

Illnesses reported in Illinois, Indiana, Kentucky, Michigan, Missouri, Ohio, and Tennessee

AAFP Still Recommends CRC Screening From Age 50 to 75

AAFP Still Recommends CRC Screening From Age 50 ...

Despite ACS change to start screening from age 45 years, AAFP agrees with USPSTF recommendation

is free, fast, and customized just for you!




Already a member?

Sign In Now »